Plain-English translation of NCT07395596 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 4 — The treatment has already been approved. Researchers are tracking how it works in a large number of people over time.
This trial is testing whether remimazolam, a newer sedation medication, works better than the standard medication (propofol) when patients need a lung scope procedure—a test doctors use to look inside the airways and diagnose or treat lung problems. The goal is to see if this medication reduces the chance that patients stop getting enough oxygen during the procedure, while also causing fewer side effects and allowing faster recovery.
Standard sedation medications used during lung scope procedures can sometimes make it harder to breathe and cause other complications. This trial exists to see whether the new treatment offers a safer option for patients with serious underlying health conditions who are at higher risk during these procedures.
You likely qualify if…
You likely don't qualify if…
If you join this trial, you will be randomly assigned to receive either the standard sedation medication or the new medication during your scheduled lung scope procedure. You will remain awake enough to breathe on your own throughout the procedure. After the procedure is complete, the research team will monitor you during recovery and track whether you experienced any complications, side effects, or breathing problems. Your participation involves the lung scope procedure itself plus follow-up monitoring to ensure your safety.
AI-generated summary from trial data · Jun 3, 2026 · Not medical advice
China